Shichiri Keiko, Tung Kaity H, Takabe Kazuaki, Bartlett David L
Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Department of Surgery, Allegheny Health Network, Pittsburgh, PA 15212, USA.
World J Oncol. 2025 Jun;16(3):243-253. doi: 10.14740/wjon2571. Epub 2025 May 13.
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver carcinoma that is composed of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Given its low incidence, there is no standardized treatment protocol or systemic regimens. With the development of immune checkpoint inhibitors (ICIs), one of the immunotherapies that modulate the immune system by restoring antitumor immune response, studies have shown promising results for the use of ICI as systemic therapy for advanced solid tumors, including liver cancers. Moreover, prospective clinical studies displayed favorable outcomes of the use of ICIs in HCC and biliary tract cancers. Here, we review the recent evidence in application and comparison of ICIs for HCC, CCA, and cHCC-CCA as well as the future direction of systemic therapy for cHCC-CCA.
肝细胞胆管癌（cHCC-CCA）是一种罕见的原发性肝癌，由肝细胞癌（HCC）和胆管癌（CCA）组成。鉴于其发病率低，尚无标准化的治疗方案或全身治疗方案。随着免疫检查点抑制剂（ICIs）的发展，免疫疗法之一是通过恢复抗肿瘤免疫反应来调节免疫系统，研究表明ICIs作为晚期实体瘤（包括肝癌）的全身治疗具有有前景的结果。此外，前瞻性临床研究显示ICIs用于HCC和胆管癌有良好的结果。在此，我们综述了ICIs用于HCC、CCA和cHCC-CCA的应用及比较的最新证据，以及cHCC-CCA全身治疗的未来方向。
